Join us for a webinar with Prof. Milena Ivanova MD (Molecular Biologist, Lab Co-Director at the Dept. of Clinical Immunology, University Hospital Aleksandrovska, Sofia, Bulgaria) and Libor Kolesár (Senior Field Applications Scientist & Assay Product Manager, Omixon).
HLA class I and class II alleles have been shown to be associated with different type of cancer including solid tumours and hematological malignancies. In this webinar we will be discussing the role of HLA class I alleles in immunoediting of JAK2 V617F driven myeloproliferative neoplasms using a population genetics approach.
Prof. Milena Ivanova MD (Molecular Biologist, Lab Co-Director-University Hospital Aleksandrovska) and Libor Kolesár (Senior FAS & Assay Product Manager-Omixon)
Agenda:
🔸 Welcome and introduction
🔸Cancer Immunoediting / Role of HLA
🔸 Role of HLA immunoedting in the development of JAK2 V617F driven myeloproliferative neoplasms
🔸 Summary
🔸 Closing remarks
🔸 Q&A
Please note that participation in this educational program provides 0.15 Continued Education Credits (CECs) accredited by the American Board of Histocompatibility and Immunogenetics (ABHI).
We are looking forward to welcoming you remotely on our next sessions in the near future. If you have any questions, please contact us directly at sales@omixon.com
